Skip to main content
S&P 5007,676.77+0.70%DOW52,361.58+0.28%NASDAQ26,169.38+0.82%BTC$80,129.00+0.25%ETH$2,324.65+0.23%GOLD$4,027.20-0.28%OIL$101.22-0.53%
Smart Investors Daily
SID Premium
AS

NASDAQ · ASMB

Assembly Biosciences, Inc.

Healthcare · Biotechnology

$19.67

Down-$0.17 (-0.86%)

Updated Oct 27, 2026, 3:01 AM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
256.95M
P/E ratio
-5.93
Dividend yield
0.00%
52-week range
$19.30 – $37.01
Volume
152.23K
Avg. volume
121.21K

Price performance · ASMB

ASMB price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 26, 2026

ASMB closed at $19.67 after 21 trading sessions, down 16.69% for the selected period.

Last close
$19.67
Period change
-16.69%
Period low
$19.67
Period high
$23.61
Daily close
View OHLC price history
ASMB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 26, 2026$19.97$20.09$19.585$19.67152.23K
Oct 23, 2026$20.34$20.34$19.30$19.84206.01K
Oct 22, 2026$20.29$20.85$19.98$20.28137.85K
Oct 21, 2026$21.42$21.93$20.38$20.46234.77K
Oct 20, 2026$20.23$21.4795$20.07$21.19222.8K
Oct 19, 2026$20.22$20.49$19.95$20.16199.16K
Oct 16, 2026$20.63$20.63$19.94$20.09167.74K
Oct 15, 2026$20.73$21.04$20.41$20.57204.26K
Oct 14, 2026$20.19$20.9899$19.98$20.53241.37K
Oct 13, 2026$22.64$22.64$20.28$20.34305.63K
Oct 12, 2026$23.43$23.83$22.44$22.77207.82K
Oct 9, 2026$23.00$23.58$22.72$23.53170.49K
Oct 8, 2026$22.78$23.05$22.08$22.82288.4K
Oct 7, 2026$21.95$23.134$21.80$22.95190.79K
Oct 6, 2026$22.84$22.92$21.80$22.18349.44K
Oct 5, 2026$22.68$22.95$22.27$22.74241.75K
Oct 2, 2026$23.30$23.4799$22.01$22.54368.31K
Oct 1, 2026$23.18$23.66$22.75$22.98350.8K
Sep 30, 2026$23.65$23.865$23.225$23.49221.15K
Sep 29, 2026$23.70$23.79$23.05$23.48229.74K
Sep 28, 2026$23.35$23.86$23.05$23.61117.45K

Latest ASMB news

The latest Smart Investors Daily articles mentioning ASMB.

Stock researchCompany · Overview

ASMB research

Overview

Company profile and research snapshot.

Company profile

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$39.00
Implied upside
—
Analysts
11
ASMB recent ratings
DateFirmRatingTarget
Sep 1, 2026MizuhoOutperform—
Sep 1, 2026UBSBuy—
Aug 18, 2026HC Wainwright & Co.Buy—
Jun 15, 2026MizuhoOutperform—
May 28, 2026GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 5, 2026

Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026

– ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction – SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced that two posters featuring new Phase 1a data from its ABI-6250 program will be presented at The Liver Meeting® 2026, the annual meeting of the American Association for the Study of Liver Diseas

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By